Everlife Biomed
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Everlife Biomed - overview
Established
2018
Location
Beijing, -, China
Primary Industry
Biotechnology
About
Established in 2018 and based in Beijing, China, Everlife Biomed is a biotechnology company that engages in the research and development of Human-derived immune-exempt cell therapy products. In February 2019, it signed a cooperation agreement with Tsinghua University Medical School. In April 2021, it signed the first clinical experimental hospital. The CEO, Jianlin Liang, is a Ph.
D. from the Tsinghua-Peking University Life Sciences Joint Center and the main inventor of the Sertoli cell core patent. The chief scientist officer, Jiakui Ji, is a professor at Tsinghua University, an expert in the field of stem cell differentiation, and the main inventor of the domestic patent of immune cell induction technology and PCT patent. The company's products can be categorized into rheumatoid arthritis cell injection, immune-exempt artificial pancreas, and assisted reproductive testing systems.
It has developed immune-exempt drugs to protect transplanted cells or tissues from host attack, to treat autoimmune diseases, or as a carrier for transplanted cells. The company generates revenue from clinical-stage cell therapy products, licensing of immune-exempt technologies, and specialized diagnostic systems in reproductive and autoimmune health. In June 2025, Everlife Biomed raised Series A funding from new investors Yuanhe Capital and Innoangel Fund.
Current Investors
Tsinghua Innovation Ventures, Lotus Lake Capital, Unity Ventures
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.everlifebiomed.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.